Holen Sie sich die Stockscreener-App
9.34
0.74%
-0.07
Handel nachbörslich:
9.34
Schlusskurs vom Vortag:
$9.41
Offen:
$9.56
24-Stunden-Volumen:
1.83M
Relative Volume:
2.19
Marktkapitalisierung:
$714.04M
Einnahmen:
$54.55M
Nettoeinkommen (Verlust:
$-193.57M
KGV:
-3.2318
EPS:
-2.89
Netto-Cashflow:
$-181.86M
1W Leistung:
-7.89%
1M Leistung:
-21.45%
6M Leistung:
-37.73%
1J Leistung:
-62.64%
1-Tages-Spanne:
$9.29
$9.645
1-Wochen-Bereich:
$9.28
$10.12
52-Wochen-Spanne:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Firmenname
Nurix Therapeutics Inc
Sektor
Branche
Telefon
(415) 660-5320
Adresse
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Vergleichen Sie NRIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.34 | 719.39M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.02 | 100.52B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.70 | 61.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.51 | 59.29B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
712.20 | 43.09B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
306.05 | 35.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-17 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-11 | Eingeleitet | Jefferies | Buy |
| 2024-09-06 | Fortgesetzt | Robert W. Baird | Outperform |
| 2024-07-31 | Eingeleitet | Truist | Buy |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-03-09 | Eingeleitet | Barclays | Overweight |
| 2023-02-28 | Eingeleitet | Oppenheimer | Outperform |
| 2022-10-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-12-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-30 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-04-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-11-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-18 | Eingeleitet | Needham | Buy |
| 2020-08-18 | Eingeleitet | Piper Sandler | Overweight |
| 2020-08-18 | Eingeleitet | Stifel | Buy |
Alle ansehen
Nurix Therapeutics Inc Aktie (NRIX) Neueste Nachrichten
Vanguard Group Inc. Boosts Stock Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
How hedge fund analytics apply to Nurix Therapeutics Inc. stockPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
Nurix Therapeutics, Inc. $NRIX Holdings Decreased by Affinity Asset Advisors LLC - MarketBeat
Is this a good reentry point in Nurix Therapeutics Inc.2025 Major Catalysts & Fast Exit and Entry Strategy Plans - Newser
Understanding Nurix Therapeutics Inc.’s price movementJuly 2025 Fed Impact & AI Powered Market Entry Strategies - Newser
What high frequency data says about Nurix Therapeutics Inc.2025 Risk Factors & Smart Money Movement Alerts - Newser
Wellington Management Group LLP Sells 397,863 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Using R and stats models for Nurix Therapeutics Inc. forecastingPortfolio Performance Summary & Stepwise Trade Execution Plans - Newser
Visualizing Nurix Therapeutics Inc. stock with heatmapsLong Setup & Real-Time Volume Spike Alerts - Newser
What machine learning models say about Nurix Therapeutics Inc.Weekly Trade Recap & Verified Momentum Watchlists - Newser
Visual analytics tools that track Nurix Therapeutics Inc. performanceCEO Change & Growth Oriented Trading Recommendations - Newser
Nurix Therapeutics, Inc. $NRIX Shares Acquired by Russell Investments Group Ltd. - MarketBeat
Volatility clustering patterns for Nurix Therapeutics Inc.Analyst Upgrade & Risk Controlled Daily Trade Plans - Newser
Using fundamentals and technicals on Nurix Therapeutics Inc.Buy Signal & Free Daily Entry Point Trade Alerts - Newser
Can a trend reversal in Nurix Therapeutics Inc. lead to recovery2025 Institutional Moves & Verified Swing Trading Watchlists - Newser
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
T. Rowe Price Investment Management Inc. Has $28.85 Million Stock Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Tools to assess Nurix Therapeutics Inc.’s risk profile2025 Winners & Losers & High Win Rate Trade Tips - Newser
Multi asset correlation models including Nurix Therapeutics Inc.2025 Winners & Losers & Fast Exit and Entry Strategy Plans - Newser
Real time scanner hits for Nurix Therapeutics Inc. explainedMarket Sentiment Review & Free High Return Stock Watch Alerts - Newser
Nurix Therapeutics (NASDAQ:NRIX) Stock Rating Upgraded by Baird R W - MarketBeat
Aug Spikes: Can Nurix Therapeutics Inc. reach resistance levels soonPortfolio Gains Summary & Comprehensive Market Scan Reports - sundaytimes.kr
Nurix Therapeutics Inc. stock retracement – recovery analysis2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
Is Nurix Therapeutics Inc. stock poised for growthWall Street Watch & Expert Verified Stock Movement Alerts - Newser
Nurix Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Protein Degradation Pioneer Nurix Therapeutics Set for Major Healthcare Conference Circuit in September 2025 - Stock Titan
Trend analysis for Nurix Therapeutics Inc. this weekShare Buyback & Verified Momentum Stock Watchlist - Newser
Is Nurix Therapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - Newser
Finanzdaten der Nurix Therapeutics Inc-Aktie (NRIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.96%
1.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):